COVID-19
New variants of COVID-19 are popping up all across the globe, including here in the United States.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Will there be enough doses of the two authorized mRNA COVID-19 vaccines to meet the lofty goal of 100 million inoculations within 100 days of the start of Joe Biden’s presidential administration?
Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in COVID-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Although there are now two authorized vaccines against COVID-19 available in the United States and a third likely on the way with Johnson & Johnson’s candidate, the nation and world are nowhere near being done with the novel coronavirus, especially with new, more contagious variants now circulating.
A total of 50 countries have reported cases of B117, the more transmissible variant of COVID-19 which was first reported in the U.K. The number of countries reporting this emerging strain is up 40 from last week.
A drop-off in virulence is possible for the SARS-CoV-2 virus -- once enough of the global population has been vaccinated or exposed to it, according to a new study from scientists at Emory University and The Pennsylvania State University.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
PRESS RELEASES